한빛사
>
한빛사논문
한빛사논문
1
- 조회345
Adv. Healthc. Mater., Dec 23 2024, | https://doi.org/10.1002/adhm.202404316
Neoantigen-Displaying Protein Nanoparticles as a Therapeutic Cancer Vaccine Against Melanoma
Yujin Kim 1,2,3,4, Seojung Lee 1,2, Jungmin Yoon 1, Yumi Shin 1, Sukmo Kang 5, Sun-Young Kim 1,2, Sangmin Woo 1, Ji-Joon Song 1, Sangyong Jon 1,2
1Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea.
2Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea.
3Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA.
4Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
5Keyfron Bio Co., Ltd., 53 Yeongudanji-ro, Ochang Cheongju, Chungcheongbuk-do, 28115, Republic of Korea.
1Department of Biological Sciences, KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea.
2Center for Precision Bio-Nanomedicine, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Daejeon, 34141, Republic of Korea.
3Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, 48109, USA.
4Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
5Keyfron Bio Co., Ltd., 53 Yeongudanji-ro, Ochang Cheongju, Chungcheongbuk-do, 28115, Republic of Korea.
Y.K. and S.L. contributed equally to this work.
Corresponding Authors: Ji-Joon Song, Sangyong Jon
Corresponding Authors: Ji-Joon Song, Sangyong Jon
Abstract
Although interest in peptide-based cancer vaccines has surged in the era of personalized immunotherapy enabled by the discovery of neoantigens, the effective generation of neoantigen-specific T cell responses has been limited. Here, a Brucella BP26 protein-based nanoparticle displaying the MHC class II-restricted melanoma neoantigen, M30, is reported for use as a therapeutic cancer vaccine. Genetic engineering of 10 tandem repeats of the M30 neoepitope to a BP26 monomer results in the self-assembled, neoantigen-displaying protein nanoparticles (BP26-M30 NPs). Subcutaneous immunization of mice with BP26-M30 NPs/CpG adjuvant leads to the activation and maturation of antigen-presenting cells in draining local lymph nodes and elicits M30-specific CD4+ T cell immune responses and immunological memory. In a mouse model of aggressive B16-F10 melanoma, immunization with BP26-M30 NPs/CpG significantly inhibits the growth of established tumors. These findings suggest that the BP26-based self-assembled protein nanoparticle has the potential to be used as a cancer vaccine platform for personalized cancer immunotherapy.
논문정보
- Research article
- 2024년 12월 (BRIC 등록일 2024-12-24)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
